Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-9 of 9 for your search:
Drug:
tipifarnib
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
UHW-AML16
, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
2.
Phase III Randomized Study of Tipifarnib as Maintenance Therapy in Patients With Acute Myeloid Leukemia in Second or Subsequent Complete Remission or in First Complete Remission
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E2902
, E2902, NCT00093470
3.
Phase I/II Study of Sorafenib in Combination With Erlotinib Hydrochloride, Tipifarnib, or Temsirolimus in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-05-02
, NABTC-05-02, NCT00335764
4.
Phase I/II Study of Tipifarnib and Sequential Paclitaxel Followed By Dose-Dense Doxorubicin Hydrochloride, Cyclophosphamide, and Tipifarnib in Patients With Stage IIB-IIIC Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NYCC-06-12-487
, 7868, NCT00470301
5.
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
02 TETE 02
, NCT00209989
6.
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
HEMOS AML 0106
, EudraCT 2007-000273-35, NCT00510939
7.
Phase II Randomized Study of Tipifarnib and Etoposide as Induction Therapy in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia (Treatment Arm II Closed to Accrual as of November 2008)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J07109
, J07109, JHOC-MD017, 8077, NCT00602771
8.
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCRR
Protocol IDs:
NCRR-M01RR00096-1001
, M01RR00096, NCT00006199
9.
Phase I Study of Tipifarnib and Bortezomib in Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MCC-14796
, 14796, 7306, NCI-7306, NCT00383474
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
